Proteinase K Market Size (2024 - 2029)

Proteinase K Market Analysis

The Proteinase K Market size is estimated at USD 78.53 million in 2024, and is expected to reach USD 102.72 million by 2029, growing at a CAGR of 5.52% during the forecast period (2024-2029).

COVID-19 had a significant impact on the growth of the market. Proteinase K had great potential in the detection of COVID-19, which contributed to providing growth avenues to the market. For instance, according to an article published in Frontiers in Cellular and Infection in Microbiology in November 2021, it was observed that proteinase K demonstrated 6% and 88% sensitivity for N and ORF1ab genes, respectively. This showed that the molecular identification of the SARS-CoV2 viral component could be carried out via PK exposure and heat treatment. This has increased its adoption in identifying coronavirus, hence impacting the market growth during the pandemic. Moreover, companies' increasing focus on developing portable and affordable RT-PCR testing kits has increased the demand for proteinase K enzymes for detecting coronavirus infection among the population. For instance, in May 2022, Genes2Me launched the COVFlu Real-Time PCR kit, which detects Influenza A/B, RSV, and SARS-CoV-2. The kit also detects patients with any known variants, including Omicron, in a single process. Thus, such developments which utilize proteinase K enzymes in various molecular biology assays are anticipated to fuel the demand for proteinase K. Currently, as the pandemic has subsided, the market has lost some traction; however, it is expected to have stable growth during the forecast period of the study.

Factors such as the rising burden of chronic disorders and infectious diseases and the growing applications of diagnostic techniques and their associated enzymes for IVD are boosting market growth.

The growing burden of chronic and infectious diseases among the population is expected to increase market growth. For instance, according to the 2022 statistics published by IDF, about 537 million people were suffering from diabetes in 2021 globally, and this number is projected to reach 643 million and 784 million by 2030 and 2045, respectively. The rising disease burden is expected to increase the adoption of proteinase K, hence bolstering market growth.

Additionally, according to the British Heart Foundation England Factsheet, published in January 2022, about 6.4 million people were living with cardiovascular diseases in England in 2021. Also, according to the March 2022 update of the Australian Bureau of Statistics, the prevalence of heart disease in Australia was 4.0% in 2020-21, which equates to about 1 million people. Also, as per the same source, in Australia, heart disease increased with age, from 2.3% of people aged 45-54 years through to 23.2% of people aged 75 years and over, with males being the most affected by it in the country. Thus, the high burden of cardiovascular diseases among the population raises the demand for early diagnosis of the condition, which can be possible from proteinase K as it breaks down proteins, many of which have been implicated in various diseases, including cardiac disease. This is anticipated to fuel market growth.

Therefore, owing to the aforementioned factors, the studied market is expected to grow over the forecast period. However, the availability of new sophisticated technologies for DNA purification is likely to hamper the growth of the proteinase K market over the forecast period.

Proteinase K Industry Segmentation

As per the scope, proteinase K is known as a proteolytic enzyme (serine protease) that is used to digest proteins and remove contamination from nucleic acid preparation. Proteinase K in nucleic acid preparations rapidly inactivates DNAases and RNases that otherwise degrade DNA and RNA during purification. Proteinase K is used for the destruction of proteins in cell lysates such as tissue and cell culture cells and for the release of nucleic acids. It is also widely used in DNA extraction for digesting contaminated proteins and protects nucleic acid from nuclease attacks. The proteinase K market is segmented by form (powder and liquid), therapeutic area (infectious diseases, diabetes, oncology, cardiology, and other therapeutic areas), and geography (North America, Europe, Asia-Pacific, and the Rest of the World). The report offers the value (in USD million) for the above segments.